ALAMEDA, Calif.--(BUSINESS WIRE)--Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced it has appointed Julianne Averill, CPA, as Chief Financial Officer. In this role, Ms. Averill will be responsible for leading all financial operations and implementing key business strategies to accelerate Alveo’s growth as the company advances its be.well™ platform, a point-of-care and at-home diagnostic tool currently under development.
“Julianne’s strong track record of driving results and accelerating growth comes at a critical time as the U.S. enters the twindemic COVID+flu season,” said Ron Chiarello, Ph.D., Chairman, CEO and Founder of Alveo. “As Alveo continues its initiative of bringing accurate, at-home testing solutions to market, Julianne’s strong financial expertise will be a valuable asset to the leadership team, ensuring we remain poised for long-term success."
Ms. Averill brings over 18 years of leadership experience in the life sciences, technology/SaaS and digital health fields as well as has participated in or led over $2B in successful strategic financing and M&A initiatives. Most recently, she served as Vice President of Finance for BlackThorn Therapeutics, driving strategic growth initiatives and investment strategies. Ms. Averill has held leadership roles at Manifest MedEx and Starwood Waypoint Residential Trust, where she successfully improved financial operations to support long-term company growth. She also served as an audit manager at Deloitte, working with various Fortune 500 and international entities in the consumer business and life sciences industries.
“I was instantly drawn to Alveo’s vision of putting an affordable, rapid at-home diagnostic tool for infectious diseases into the hands of consumers worldwide,” said Ms. Averill. “Alveo has a strong leadership team, a unique solution and tremendous potential. I am thrilled to be joining the company at this exciting stage of its development. I look forward to leveraging my experience to help drive growth at Alveo as it continues on the trajectory of transforming the way infectious diseases are detected and managed.”
Alveo is leading the transformation of the consumer health tech market with a low-cost, easy-to-use, at-home diagnostic platform that will change the way infectious diseases are detected and managed. The company’s be.well™ testing system gives individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections, including COVID-19, Influenza A/B and RSV, Alveo’s agile and dynamic diagnostic platform can be adapted to detect a wide range of diseases that threaten public health. Affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will know sooner, act faster and make better-informed decisions toward personalized intervention options that benefit individuals and the entire population. To learn more, visit https://alveotechnologies.com/.